English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

The comparison of the pharmacological properties, clinical efficacy of furosemide and torasemide in patients with hypertension and edema. Torasemid similar to furosemide mechanism of diuretic action but has a higher bioavailability (&gt;80%) and a longer half-life (3-4 h). In-non-diuretic doses (2.5-5 mg/day) torasemide used in the treatment of essential hypertension, both as monotherapy and in combination with other antihypertensive drugs. When used in these doses torasemide reduces diastolic blood pressure to below 90 mm Hg in 70-80% of patients. In patients with chronic heart failure torasemide in a dose of from 5 to 20 mg/day is an effective diuretic. The bioavailability of torasemide when administered in patients with CHF decreases only slightly, the diuretic action is smoother, it is less likely to cause the phenomenon of "rebound". Total and cardiovascular mortality in patients treated with torasemide, was lower (2.2% compared with 4.5% in the comparison group; p

Loop diuretics in the treatment of hypertension and edema syndrome